^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
Published date:
01/12/2021
Excerpt:
...4 cohorts according to PD-L1 tumor proportion score (TPS) to receive camrelizumab at 200 mg IV Q2W…median follow-up was 22.9 months (95% CI 21.7–24.2). Median OS and PFS was 14.8 months (95% CI 10.3–18.8) and 3.2 months (95% CI 2.0–3.4), respectively. Third-line therapy and beyond was received by 65 (44.5%) patients. PFS2 was 10.0 months (95% CI 8.2–12.4)...Patients with positive PD-L1 expression derived greater benefit from camrelizumab...Table 1
Trial ID:
Source:
Title:
P1.01-61 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
Excerpt:
Camrelizumab (SHR-1210) is a potent anti-PD-1 monoclonal antibody and has shown promising activity in NSCLC in Phase I studies….Subgroup analysis showed increased PD-L1 expression was associated with better response rate.
DOI:
https://doi.org/10.1016/j.jtho.2019.08.776
